C2N Diagnostics

Business Services · Missouri, United States · 51-200 Employees

View Company Info for Free

Overview

Headquarters

20 S Sarah St, St. Louis, Missouri, 6310...

Phone Number

(877) 226-3424

Revenue

$19.4 Million

Industry

Business Services Healthcare Services Research & Development Medical Laboratories & Imaging Centers
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1

About C2N Diagnostics

C2N Diagnostics (www.c2ndiagnostics.com) was formed by scientific co-founders Drs. David Holtzman and Randall Bateman of Washington University School of Medicine in St. Louis, MO and LifeTech Research, a technology research and venture development firm (www.lifetechresearch.com). C2N is commercializing a suite of biomarker tests to enable early detection of debilitating neurodegenerative disorders before symptom onset, facilitate drug discovery, and enhance clinical drug development at lower risk and cost. Besides its biomarker platform, C2N is also developing therapeutics for neurodegenerative disorders. In March 2015, C2N formed a global partnership with AbbVie to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer's Disease and other neurological disorders. AbbVie is currently conducting phase 2 trials with the lead candidate ABBV-8E12 in Alzheimer's disease and Progressive Supranuclear Palsy.Explore more
Popular SearchesC2n Diagnostics LLCC2N DiagnosticsSt Louis Diagnostics IncC N's DiagnosticsSIC Code 87,873NAICS Code 54,541Show more

C2N Diagnostics Org Chart

PhoneEmail
RR
United States flag for contact location.

Controller

Flame icon indicating likelihood to engage via phone.PhoneEmail

PhoneEmail
Get the full picture
Sign in to uncover key details.

Is C2N Diagnostics your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Recommended Actions

Illustration of an envelope

Company Profile Activity

i

Among all Business Services companies

Low Activity

High Activity

Activity Insights

C2N Diagnostics is experiencing very low activity levels compared to other companies in the Business Services sector.

What does this means?

C2N Diagnostics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about C2N Diagnostics.

C2N Diagnostics Tech Stack

A closer look at the technologies used by C2N Diagnostics

Top Business Services Companies

Frequently Asked Questions Regarding C2N Diagnostics

What is C2N Diagnostics's official website?
C2N Diagnostics's official website is www.c2ndiagnostics.com
What is C2N Diagnostics's Revenue?
C2N Diagnostics's revenue is $19.4 Million
What is C2N Diagnostics's SIC code?
C2N Diagnostics's SIC: 87,873
What is C2N Diagnostics's NAICS code?
C2N Diagnostics's NAICS: 54,541
How many employees does C2N Diagnostics have?
C2N Diagnostics has 51-200 employees
What industry does C2N Diagnostics belong to?
C2N Diagnostics is in the industry of: Business Services, Healthcare Services, Research & Development
What technology does C2N Diagnostics use?
Some of the popular technologies that C2N Diagnostics uses are: Proofpoint, Microsoft 365, Squarespace, Microsoft Exchange Online
How do I contact C2N Diagnostics?
C2N Diagnostics contact info: Phone number: (877) 226-3424 Website: www.c2ndiagnostics.com
What does C2N Diagnostics do?

C2N Diagnostics (www.c2ndiagnostics.com) was formed by scientific co-founders Drs. David Holtzman and Randall Bateman of Washington University School of Medicine in St. Louis, MO and LifeTech Research, a technology research and venture development firm (www.lifetechresearch.com). C2N is commercializing a suite of biomarker tests to enable early det... ection of debilitating neurodegenerative disorders before symptom onset, facilitate drug discovery, and enhance clinical drug development at lower risk and cost. Besides its biomarker platform, C2N is also developing therapeutics for neurodegenerative disorders. In March 2015, C2N formed a global partnership with AbbVie to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer's Disease and other neurological disorders. AbbVie is currently conducting phase 2 trials with the lead candidate ABBV-8E12 in Alzheimer's disease and Progressive Supranuclear Palsy.Read More

Is C2N Diagnostics a public company?
C2N Diagnostics is private company therefore does not currently have an official ticker symbol
See more information about C2N Diagnostics

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.